Clearbridge Investments, LLC Rotates From Mega-Cap AI Winners To Defensives

The biggest incremental dollar adds cluster around four ideas: scalable drug franchises, non-glamour semis, boring-but-essential infrastructure, and asset-light financial platforms. The new and increased positions are not moonshots; they are durable cash-flow stories Clearbridge is willing to size up when others are distracted by AI headlines.

• AstraZeneca (AZN) is the lone new top-50 position, instantly sized to 0.89% of the book at roughly $1.02B. That is a statement entry: leaning into big-cap pharma’s pipeline and pricing power just as investors debate the durability of high-multiple software and semis.

• Honeywell (HON) is effectively re-underwritten, with position size up 170.3% and about $392.3M of incremental capital. Clearbridge is aligning with an industrial and aerospace platform leveraged to automation, defense, and mission-critical controls rather than volume-sensitive manufacturing.

• Netflix (NFLX) sees a 17.3% share add and about $277.7M more capital, signaling belief that its pivot to ad-supported tiers and content discipline is still underappreciated. It’s one of the few large-cap, asset-light consumer names they are adding to rather than trimming.

• Inside semis, they increase Taiwan Semi (TSM) by 7.5% and Texas Instruments (TXN) by 42.5%, together deploying roughly $364.8M. This is a rotation from AI superstar silicon into the quieter foundry and analog rails that will be needed regardless of which AI vendor wins.

• Marsh & McLennan (MRSH) and Apollo (APO) get aggressive capital, with position sizes up 26.5% and 64.2% respectively and roughly $459.1M added between them. That looks like a bet that fee and spread-based financials compound through volatility while banks and fintech debate regulation and credit cycles.

• Williams (WMB) gets a 9.0% share increase and about $139.3M more, reinforcing a theme: own the pipelines and midstream assets that clip cash flows off energy demand, rather than swing with commodity prices.

On the sell side, Clearbridge isn’t capitulating on themes; it’s skimming its fattest profit pools. The biggest trims read like a who’s-who of the last two years’ index darlings and cyclical beta.

• Amazon (AMZN) and Broadcom (AVGO) are the two largest dollar cuts, at about $470.1M and $468.8M. Given Amazon is still 2.62% of the book and Broadcom 2.24%, this looks like sizing discipline in richly valued leaders, not a thesis reversal.

• Microsoft (MSFT) and Apple (AAPL) see meaningful reductions of about $402.6M and $242.5M, and Nvidia (NVDA) is also gently trimmed. Clearbridge is acknowledging that these core AI and platform holdings have done exactly what they hoped; now they can finance health care and quality defensives without relying on inflows.

• In semis and hardware, ASML is cut by 20.1% (about $307.9M), while high-beta AI ecosystem name Vertiv (VRT) is trimmed. That’s consistent with dialing back the most cyclical or sentiment-driven parts of the hardware stack.

• Commodity and cyclical risk comes down: Exxon Mobil (XOM) is reduced by 23.3% (roughly $356.2M), Freeport-McMoRan (FCX) by 25.3% (about $222.0M), and Tesla (TSLA) by 24.8% (around $208.2M). The message: keep some upside, but shrink exposure to narratives that swing with macro data and policy tweets.

• Banks and interest-rate sensitives like Bank of America (BAC) and ISRG in medtech are trimmed even as Clearbridge adds to more controlled financial plays (APO, MRSH) and new pharma (AZN). They’re upgrading quality and visibility within each sector, not bailing on the categories altogether.

The sector chart shows a manager that is still structurally overweight technology but less willing to be hostage to a single factor regime. Tech slips from 46.46% to 44.88%, while health care, utilities, finance, and real estate quietly take more of the load.

Health care jumps from 6.27% to 7.7%, driven by the new AstraZeneca stake and higher weights in names like Johnson & Johnson and Becton Dickinson. This tilt toward large-cap pharma and medtech is a hedge against both cyclicals and growth multiple compression.

Finance climbs from 6.51% to 6.95% as Clearbridge adds to specialty insurers and alternative asset managers while trimming traditional banks. They prefer fee streams and underwriting margins over pure balance-sheet leverage.

Utilities edge up from 4.44% to 4.78%, with adds to Williams and Entergy, while Waste Management remains a core quasi-utility. Real estate also ticks up from 3.95% to 4.08% as they build American Tower, pairing tower cash flows with Visa’s payments tollbooth economics.

On the flip side, energy falls from 2.35% to 1.85% almost entirely via the Exxon trim, and basic materials dip from 4.45% to 4.32% after cutting Freeport. Industrials slide modestly from 10.28% to 10.03% as they rotate within the sector, taking down RTX, UNP, L3Harris, and Thermo Fisher to fund the big add in Honeywell and incremental Vulcan.

Taken together, Clearbridge is positioning for a world where AI and digital platforms remain central, but returns are increasingly harvested through the boring plumbing and the cash-flow neighbors, not just the marquee names. They are not abandoning their winners; they are right-sizing them to make room for health care, utilities, and high-quality financials that can defend capital if multiples crack.

The internal rotation within semis — away from ASML and Broadcom exposure at the margin, toward TSM and Texas Instruments — points to a preference for businesses tied to volume and breadth of compute rather than just leading-edge scarcity. That is a bet that demand normalizes but remains structurally higher, rewarding scale and diversification.

The build-out in pharma and medtech, alongside resilient consumer and staples like Procter & Gamble and Coca-Cola, suggests Clearbridge is comfortable owning slower, steadier EPS growth if it comes with pricing power and dividends. Their increased stakes in pipelines, towers, and waste management deepen a backbone of quasi-regulated, inflation-linked cash flows.

Financials are the quiet wildcard. By boosting Apollo and Marsh & McLennan while trimming money-center banks, Clearbridge is aligning with capital-light, fee-driven models that benefit from volatility and complexity rather than zero-rate stimulus.

If the next few years look more like a grind than a melt-up, this book is built to clip coupons, compound at mid-teens, and still participate meaningfully if AI-driven earnings keep surprising to the upside. Future quarters will show whether they keep pressing this barbell, or reload on high-beta tech if the market gives them a better entry.